PSA testing without clinical indication for prostate cancer in relation to socio-demographic and clinical characteristics in the Danish Diet, Cancer and Health Study

References

• Dutta RS, Philip J, Javle P. Trends in prostate cancer incidence and survival in various socioeconomic classes: A population-based study. Int J Urol 2006;13:1364.
   PubMed Web of Science ®Google Scholar
• Lund Nilsen TI, Johnsen R, Vatten LJ. Socio-economic and lifestyle factors associated with the risk of prostate cancer. Br J Cancer 2000;82:1358–63.
   PubMed Web of Science ®Google Scholar
• Marsa K, Johnsen NF, Bidstrup PE, Johannesen-Henry CT, Friis S. Social inequality and incidence of and survival from male genital cancer in a population-based study in Denmark, 1994–2003. Eur J Cancer 2008;44:2018–29.
   PubMed Web of Science ®Google Scholar
• Rapiti E, Fioretta G, Schaffar R, Neyroud-Caspar I, Verkooijen HM, Schmidlin F, et al. Impact of socioeconomic status on prostate cancer diagnosis, treatment, and prognosis. Cancer 2009;115:5556–65.
   PubMed Web of Science ®Google Scholar
• Hoffman RM, Stone SN, Espey D, Potosky AL. Differences between men with screening-detected versus clinically diagnosed prostate cancers in the USA. BMC Cancer 2005; 5:27.
   PubMed Web of Science ®Google Scholar
• Jonsson H, Holmstrom B, Duffy SW, Stattin P. Uptake of prostate-specific antigen testing for early prostate cancer detection in Sweden. Int J Cancer 2011;129:1881–8.
   PubMed Web of Science ®Google Scholar
• Drazer MW, Huo D, Schonberg MA, Razmaria A, Eggener SE. Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States. J Clin Oncol 2011;29:1736–43.
   PubMed Web of Science ®Google Scholar
• Ross LE, Coates RJ, Breen N, Uhler RJ, Potosky AL, Blackman D. Prostate-specific antigen test use reported in the 2000 National Health Interview Survey. Prev Med 2004;38:732–44.
   PubMed Web of Science ®Google Scholar
• Chou R, Croswell JM, Dana T, Bougatsos C, Blazina I, Fu R, et al. Screening for prostate cancer: A review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2011;155:762–71.
   PubMed Web of Science ®Google Scholar
• Mettlin C, Jones G, Averette H, Gusberg SB, Murphy GP. Defining and updating the American Cancer Society guidelines for the cancer-related checkup: Prostate and endometrial cancers. CA Cancer J Clin 1993;43:42–6.
   PubMed Web of Science ®Google Scholar
• Lin K, Lipsitz R, Miller T, Janakiraman S. Benefits and harms of prostate-specific antigen screening for prostate cancer: An evidence update for the U.S. Preventive Services Task Force. Ann Intern Med 2008;149:192–9.
   PubMed Web of Science ®Google Scholar
• Brasso K, Friis S, Kjaer SK, Jorgensen T, Iversen P. Prostate cancer in Denmark: A 50-year population-based study. Urology 1998;51:590–4
   PubMed Web of Science ®Google Scholar
• The Danish Urological Society. DACROPA. Available from: http://ducg dk/prostata/retningslinjer/2011. [cited 5 May 2013].
   Google Scholar
• Borre M. Screening by lower urinary tract symptoms vs asymptomatic prostate-specific antigen levels leading to radical prostatectomy in Danish men: Tumour characteristics and treatment outcome. Br J Urol Int 2009; 104:205–8.
   Google Scholar
• Tjonneland A, Olsen A, Boll K, Stripp C, Christensen J, Engholm G, et al. Study design, exposure variables, and socioeconomic determinants of participation in Diet, Cancer and Health: A population-based prospective cohort study of 57,053 men and women in Denmark. Scand J Public Health 2007;35:432–41.
   PubMed Web of Science ®Google Scholar
• Gjerstorff ML. The Danish Cancer Registry. Scand J Public Health 2011;39:42–5.
   PubMed Web of Science ®Google Scholar
• Finney Rutten LJ, Meissner HI, Breen N, Vernon SW, Rimer BK. Factors associated with men’s use of prostate-specific antigen screening: Evidence from Health Information National Trends Survey. Prev Med 2005;40:461–8.
   PubMed Web of Science ®Google Scholar
• Goldman DP, Smith JP. Can patient self-management help explain the SES health gradient?. Proc Natl Acad Sci U S A 2002;99:10929–34.
   PubMed Web of Science ®Google Scholar
• Mukai TO, Bro F, Pedersen KV, Vedsted P. [Use of prostate-specific antigen testing]. Ugeskr Laeger 2010;172:696–700.
   PubMedGoogle Scholar
• Schymura MJ, Kahn AR, German RR, Hsieh MC, Cress RD, Finch JL, et al. Factors associated with initial treatment and survival for clinically localized prostate cancer: Results from the CDC-NPCR Patterns of Care Study (PoC1). BMC Cancer 2010;10:152.
   PubMed Web of Science ®Google Scholar
• Kane CJ, Lubeck DP, Knight SJ, Spitalny M, Downs TM, Grossfeld GD, et al. Impact of patient educational level on treatment for patients with prostate cancer: Data from CaPSURE. Urology 2003;62:1035–9.
   PubMed Web of Science ®Google Scholar
• Andriole GL, Crawford ED, Grubb RL, III, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360: 1310–9.
   PubMed Web of Science ®Google Scholar
• Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010;11:725–32.
   PubMed Web of Science ®Google Scholar
• Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012;366:981–90.
   PubMed Web of Science ®Google Scholar
• Finne P, Fallah M, Hakama M, Ciatto S, Hugosson J, de KH, et al. Lead-time in the European randomised study of screening for prostate cancer. Eur J Cancer 2010;46: 3102–8.
   PubMed Web of Science ®Google Scholar
• Larsen SB, Dalton SO, Schuz J, Christensen J, Overvad K, Tjonneland A, et al. Mortality among participants and non-participants in a prospective cohort study. Eur J Epidemiol 2012;27:837–45.
   PubMed Web of Science ®Google Scholar